BCL2 and plasma cell myeloma: Here we provide preclinical and clinical evidence in multiple myeloma for the efficacy and mechanism of statin-mediated sensitization to apoptosis by BH3 mimetics against BCL2 (venetoclax) or MCL-1 (S63845).